Trials / Completed
CompletedNCT03085381
A Phase I Study of Quadrivalent HPV Recombinant Vaccine
A Randomized, Double-Blind and Placebo-Controlled Phase I Study to Evaluate the Safety and Primary Immunogenicity of the Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant Vaccine (Hansenula Polymorpha) in Chinese Female Subjects Aged 9-45 Years
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 90 (actual)
- Sponsor
- Shanghai Bovax Biotechnology Co., Ltd. · Industry
- Sex
- Female
- Age
- 9 Years – 45 Years
- Healthy volunteers
- Accepted
Summary
To evaluate the safety and primary immunogenicity of the quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine (hansenula polymorpha) in Chinese female subjects aged 9-45 years.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | HPV vaccine | |
| BIOLOGICAL | Placebo |
Timeline
- Start date
- 2016-12-01
- Primary completion
- 2017-10-01
- Completion
- 2018-08-01
- First posted
- 2017-03-21
- Last updated
- 2018-09-14
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT03085381. Inclusion in this directory is not an endorsement.